Journal
CURRENT CLINICAL MICROBIOLOGY REPORTS
Volume 6, Issue 4, Pages 193-199Publisher
SPRINGER
DOI: 10.1007/s40588-019-00134-3
Keywords
HSV; Oncolytic; Herpesvirus; VC2
Categories
Funding
- Louisiana Board of Regents Governor's Biotechnology grant
- NIH [GM103424, GM110760]
- National Institutes of Health COBRE grant [P20 GM121288]
Ask authors/readers for more resources
Purpose between safety, immunogenicity, and replicative potential. We have undertaken this review to better understand how these considerations can be incorporated into rational approaches to the design of novel herpesvirus oncolytic virotherapies. Recent Findings Several recent papers have demonstrated that enhancing the potential of HSV-1 oncolytic viruses to combat antiviral mechanisms present in the tumor microenvironment leads to greater efficacy than their parental viruses. Summary It is not entirely clear how the immunosuppressive tumor microenvironment affects oncolytic viral replication and spread within tumors. Recent work has shown that the manipulation of specific cellular and molecular mechanisms of immunosuppression operating within the tumor microenvironment can enhance the efficacy of oncolytic virotherapy. We anticipate that future work will integrate greater knowledge of immunosuppression in tumor microenvironments with design of oncolytic virotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available